Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs

Novartis: The Sell-Off Creates An Attractive Entry Point

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

US FDA expands use of Novartis drug for chronic skin condition

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal

Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal

Novartis signs mRNA deal for about $7.8 billion with China's Abogen

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

Novartis AG (NVS) Shares Fall 0.8% -- What GF Score of 78 Tells Investors

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

Novartis (NYSE:NVS) Stock Sold by Rep. Kevin Hern

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

Critical Analysis: Redhill Biopharma (NASDAQ:RDHL) versus Novartis (NYSE:NVS)